ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Molecular and Cellular Biology

• Publication date

  1994-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/mcb.14.6.3550-3558.1994PMID 7515147PMCID PMC358722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SH 2 Domains Recognize Specific Phosphopeptide Sequences

  2004cited by this paper
• Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members

  1994cited by this paper
• The erbB3 gene product is a receptor for heregulin.

  1994cited by this paper
• Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells.

  1993influential reference
• Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.

  1993cited by this paper
• Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells.

  1993cited by this paper
• SH2 domains recognize specific phosphopeptide sequences.

  1993cited by this paper
• Insulin-stimulated phosphatidylinositol 3-kinase. Association with a 185-kDa tyrosine-phosphorylated protein (IRS-1) and localization in a low density membrane vesicle.

  1993cited by this paper
• CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase.

  1993cited by this paper
• Expression of the c-erbB-3 protein in normal human adult and fetal tissues.

  1992cited by this paper
• Expression and characterization of the p85 subunit of the phosphatidylinositol 3-kinase complex and a related p85 beta protein by using the baculovirus expression system.

  1992cited by this paper
• Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation.

  1992cited by this paper
• Phosphatidylinositol 3-kinase is activated by nerve growth factor and epidermal growth factor in PC12 cells.

  1992cited by this paper
• Activation of phosphatidylinositol 3-kinase by epidermal growth factor, basic fibroblast growth factor, and nerve growth factor in PC12 pheochromocytoma cells.

  1992cited by this paper
• Interactions of polyomavirus middle T with the SH2 domains of the pp85 subunit of phosphatidylinositol-3-kinase

  1992cited by this paper
• Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit.

  1992cited by this paper
• Insulin treatment stimulates the tyrosine phosphorylation of the alpha-type 85-kDa subunit of phosphatidylinositol 3-kinase in vivo.

  1992cited by this paper
• Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase.

  1992cited by this paper
• Expression and function of IRS-1 in insulin signal transmission.

  1992influential reference
• Interaction between the epidermal growth factor receptor and phosphoinositide kinases.

  1991cited by this paper
• Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein

  1991influential reference
• Oncogenes and signal transduction.

  1991cited by this paper
• Epidermal growth factor-activated calcium and potassium channels.

  1991cited by this paper
• Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase.

  1991cited by this paper
• Role of inositol (1,4,5)trisphosphate in epidermal growth factor-induced Ca2+ signaling in A431 cells.

  1991cited by this paper
• Anti-phosphotyrosine immunoprecipitation of phosphatidylinositol 3' kinase activity in different cell types after exposure to epidermal growth factor.

  1990cited by this paper
• Epidermal growth factor increases the labeling of phosphatidylinositol 3,4-bisphosphate in MA-10 Leydig tumor cells.

  1990cited by this paper
• Human platelets form 3-phosphorylated phosphoinositides in response to alpha-thrombin, U46619, or GTP gamma S.

  1990cited by this paper
• Molecular cloning and expression of an additional epidermal growth factor receptor-related gene.

  1990cited by this paper
• Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation.

  1990cited by this paper
• Phosphatidylinositol kinase or an associated protein is a substrate for the insulin receptor tyrosine kinase.

  1990cited by this paper
• Purification and characterization of phosphoinositide 3-kinase from rat liver.

  1990cited by this paper
• Activation of phosphatidylinositol 3-kinase by insulin.

  1990cited by this paper
• Epidermal growth factor.

  1990cited by this paper
• Relationship between phosphoinositide kinase activities and protein tyrosine phosphorylation in plasma membranes from A431 cells.

  1990cited by this paper
• Thrombin stimulates the production of a novel polyphosphoinositide in human platelets.

  1990cited by this paper
• PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells.

  1989cited by this paper
• Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro.

  1989cited by this paper
• EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling.

  1989cited by this paper
• Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors.

  1989cited by this paper
• Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils.

  1989cited by this paper
• Epidermal growth factor stimulates tyrosine phosphorylation of phospholipase C-II independently of receptor internalization and extracellular calcium.

  1989cited by this paper
• Growth factor receptor tyrosine kinases.

  1988cited by this paper
• Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3.

  1988cited by this paper
• After insulin binds.

  1987cited by this paper
• Evidence for two distinct phosphatidylinositol kinases in fibroblasts. Implications for cellular regulation.

  1987cited by this paper
• Epidermal growth factor stimulates the production of phosphatidylinositol monophosphate and the breakdown of polyphosphoinositides in A431 cells.

  1987cited by this paper
• Epidermal growth factor stimulates the rapid accumulation of inositol (1,4,5)-trisphosphate and a rise in cytosolic calcium mobilized from intracellular stores in A431 cells.

  1987cited by this paper
• Separation and characterization of a phosphatidylinositol kinase activity that co-purifies with the epidermal growth factor receptor.

  1985cited by this paper
• Epidermal growth factor

  1972cited by this paper

• Pattern of HER2 and HER3 Overexpression in Patients with Pancreatic Ductal Adenocarcinoma.

  2026cites this paper
• Large-scale control over collective cell migration using light-activated epidermal growth factor receptors.

  2025cites this paper
• Computational analysis of circRNA-related competing endogenous RNA networks in HIF-1 signaling of gastric cancer

  2025cites this paper
• TNF‐α‐Driven Changes in Polarized EGF Receptor Trafficking Facilitate Phosphatidylinositol 3‐Kinase/Protein Kinase B Signaling From the Apical Surface of MDCK Epithelial Cells

  2025cites this paper
• Global signal peptide profiling reveals principles of selective Sec61 inhibition

  2024cites this paper
• HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway

  2024cites this paper
• Large-scale control over collective cell migration using light-controlled epidermal growth factor receptors

  2024cites this paper
• Bilateral regulation of EGFR activity and local PI(4,5)P2 dynamics in mammalian cells observed with superresolution microscopy

  2024cites this paper
• LRG1 promotes metastatic colorectal cancer growth through HER3 signaling.

  2024cites this paper
• Busting the Breast Cancer with AstraZeneca's Gefitinib

  2023cites this paper
• Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in Breast Cancer Brain Metastasis

  2023cites this paper
• HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer

  2023cites this paper
• Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small celllung cancer.

  2022cites this paper
• Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

  2022cites this paper
• Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases

  2022cites this paper
• HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer

  2022cites this paper
• Cell Signaling Pathways That Promote Radioresistance of Cancer Cells

  2022cites this paper
• Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes

  2022cites this paper
• Network Pharmacology Analysis, Molecular Docking, and In Vitro Verification Reveal the Action Mechanism of Prunella vulgaris L. in Treating Breast Cancer

  2022cites this paper
• Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity

  2022cites this paper
• Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers

  2022cites this paper
• HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib

  2021cites this paper
• Circ_0000215 Exerts Oncogenic Function in Nasopharyngeal Carcinoma by Targeting miR-512-5p

  2021cites this paper
• Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer

  2021cites this paper
• Mechanism underlying resveratrol's attenuation of paclitaxel cytotoxicity in human breast cancer cells: Role of the SIRT1-FOXO1-HER3 signaling pathway.

  2021cites this paper
• Role of HOXC10 in Cancer

  2021cites this paper
• HER 3 PET Imaging Identi � es HER 2 + Breast Cancers That Bene � t From HER 3 Inhibitor Addition

  2021cites this paper
• Targeting PI3K/Akt signal transduction for cancer therapy

  2021influential citation
• Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer.

  2021cites this paper
• ERBB3-dependent AKT and ERK pathways are essential for atrioventricular cushion development in mouse embryos

  2021cites this paper
• A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy.

  2021cites this paper
• Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma

  2021cites this paper
• DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma

  2021cites this paper
• Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.

  2020cites this paper
• miR-17-5p and miR-20a-5p suppress postoperative metastasis of hepatocellular carcinoma via blocking HGF/ERBB3-NF-κB positive feedback loop

  2020cites this paper
• HOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis

  2020cites this paper
• Paired genetic analysis by next‐generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis

  2020cites this paper
• HER family in cancer progression: From discovery to 2020 and beyond.

  2020cites this paper
• HER3 PET Imaging Identifies HER2+ Breast Cancers That Benefit From HER3 Inhibitor Addition  

  2020cites this paper
• Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3.

  2019cites this paper
• Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer

  2019cites this paper
• Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer

  2019cites this paper
• HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma

  2019cites this paper
• Radiation‐activated prosurvival signaling pathways in cancer cells

  2019cites this paper
• Biallelic ERBB3 loss-of-function variants are associated with a novel multisystem syndrome without congenital contracture

  2019cites this paper
• ENGINEERED MULTIVALENCY FOR ENHANCED AFFIBODY-BASED HER3 CANCER THERAPY

  2018cites this paper
• Analyse protéomique de la coordination dynamique par la protéine adaptatrice GRB2 des réseaux de signalisation cellulaire dans le cancer du sein HER2

  2018cites this paper
• Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

  2018cites this paper
• The Interplay among PINK1/PARKIN/Dj-1 Network during Mitochondrial Quality Control in Cancer Biology: Protein Interaction Analysis

  2018cites this paper
• The role of ErbB3 binding protein 1 in cancer: Friend or foe?

  2018cites this paper
• The role of transmembrane mucin protein MUC1 in anoikis and in EGFR activation of human epithelial cancer cells

  2018cites this paper
• Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo

  2018cites this paper
• Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation

  2018influential citation
• PRP4K IS A NOVEL HER2-REGULATED MODIFIER OF ANOIKIS AND TAXANE RESISTANCE

  2018influential citation
• HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.

  2018cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1469 Novel Roles of the Ack 1 Kinase in Epithelial Biology

  2018cites this paper
• Glucocorticoid receptor regulates expression of microRNA-22 and downstream signaling pathway in apoptosis of pancreatic acinar cells

  2018cites this paper
• Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma

  2018cites this paper
• Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response

  2018cites this paper
• Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling.

  2018cites this paper
• Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients

  2017cites this paper
• Modulators of Redox Metabolism in Head and Neck Cancer

  2017cites this paper
• NRG-1 Stimulates Serum DJ-1 Increase in Breast Cancers

  2017cites this paper
• Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine

  2017cites this paper
• Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.

  2017cites this paper
• siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells

  2017cites this paper
• Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions.

  2017cites this paper
• Next generation sequencing identifies 'interactome' signatures in relapsed and refractory metastatic colorectal cancer.

  2017cites this paper
• Fundamental Pathways in Breast Cancer 1: Signaling from the Membrane

  2017cites this paper
• Metformin and mTOR Inhibitors: Allies against Ovarian and Breast Cancers

  2017cites this paper
• Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells

  2017cites this paper
• Extracellular matrix in mammary gland development and breast cancer progression

  2017cites this paper
• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

  2017influential citation
• Targeting MicroRNA Function in Acute Pancreatitis

  2017cites this paper
• Development and Evaluation of 18F-IRS for Molecular Imaging Mutant EGF Receptors in NSCLC

  2017cites this paper
• Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas

  2017cites this paper
• Characterization and Applications of Single-Domain Antibody Mimics against ErbB 3

  2016cites this paper
• N-glycans of growth factor receptors: their role in receptor function and disease implications.

  2016cites this paper
• Exploring Missense Mutations in Tyrosine Kinases Implicated with Neurodegeneration

  2016cites this paper
• Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation

  2016cites this paper
• Prognostic factors in periampullary adenocarcinoma. A retrospective study over an 11 year period.

  2016cites this paper
• Bimolecular complementation affinity purification (BiCAP) reveals dimer-specific protein interactions for ERBB2 dimers

  2016cites this paper
• Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer

  2016cites this paper
• Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds

  2016cites this paper
• Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma

  2016cites this paper
• Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas

  2016cites this paper
• Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells

  2016cites this paper
• A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response

  2016cites this paper
• The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness

  2016cites this paper
• FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling

  2016cites this paper
• Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin

  2016cites this paper
• The paradox role of caspase cascade in ionizing radiation therapy

  2016cites this paper
• Disease-associated glycans on cell surface proteins.

  2016influential citation
• Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma

  2016cites this paper
• Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors

  2016cites this paper
• HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

  2016cites this paper
• HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy.

  2016cites this paper
• The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family

  2016influential citation
• Feedback activation of HER 3 attenuates response to EGFR inhibitors in colon cancer cells

  2016cites this paper
• Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib

  2015cites this paper